Actual results may differ materially, and we disclaim any obligation to update any forward-looking statements or outlook. A historical reconciliation to comparable GAAP metrics can be found in today's earnings release. We delivered $185 million in revenue, which was 10% year-on-year growth and a 2% beat from the high end of our guidance. Meanwhile, our Q3 adjusted EBITDA margin was 60%, or $111 million, which was 7% above the high end of our guidance.
All in, we had a better than expected third quarter and another record upfront annual buying season. Our unique active users on a quarterly, monthly, weekly, and daily basis all hit fresh highs, with record usage of our Newsfeed, workflow, and AI products. Our workflow users saw the largest sequential gain we've ever had, with a record 720,000 unique active prescribers in Q3. Outside of hospitals, we have not yet commercialized our AI tools, so we have not included any revenue upside for AI in our current guidance.
With that, I'll hand it over to our Audit Committee Chair and board member, Tim Cabral, to discuss our financials and guidance, Tim? Third quarter revenue grew to $185.1 million, up 10% year-over-year and exceeding the high end of our guidance range. Similar to prior quarters, our existing customers continue to lead our growth. We finished the quarter with a net revenue retention rate of 112% on a trailing twelve-month basis.